Industrials
Halma plc(HLMAF)
Live Price
Offline$51.99
+1.62% today
1Y Change
+18.91%
Window
Jun 25, 2025 โ Jun 23, 2026
- Market Cap
- $16.65B
- Revenue Growth
- +10.5%
- EPS Growth
- +9.9%
- Dividend Yield
- 0.5%
Coverage: 249 bars ยท Jun 25, 2025 โ Jun 23, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Halma plc (HLMAF) is a Industrials stock with a market cap of $16.65B and listed on OTC. The stock last traded around $51.99 and up 18.9% across the available one-year price window (Jun 25, 2025 โ Jun 23, 2026). Baseline metrics include revenue growth of +10.5%, EPS growth of +9.9%, a dividend yield of 0.5%. What stands out right now is revenue +10.5%, EPS +9.9%, free cash flow +29.9% with operating margin 20.2% and ROIC 9.6%. The dividend is present but secondary, with a yield around 0.5%. Valuation already assumes a fairly strong business story at P/E 62.4 and price/sales 9.1. Stock Foundry combines HLMAF price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Industrials peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Above sector median
+10.5% vs +3.6% peer median
Operating Margin
Above sector median
+20.2% vs +16.9% peer median
P/E
Above sector median
62.4 vs 36.7 peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on Jun 11, 2026, but the surprise data is still limited.
The operating story is still moving forward
Revenue is running at +10.5% and EPS at +9.9%, with operating margin around 20.2%.
Shareholder return is still part of the story
The stock is still offering a dividend yield around 0.5%, which matters if the thesis depends on income as much as growth.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged +3.1% over the next 5 trading days and finished higher after 2 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 Jun 11, 2026 | โ | -3.6% | -4.9% | โ |
2025 Nov 19, 2025 | +3.8% | +10.8% | +13.0% | +9.1% |
2025 Jun 11, 2025 | -57.2% | +4.9% | +1.2% | +1.5% |
Benchmark Edge
HLMAF vs SPY, QQQ, and Sector ETFs
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
HLMAF
โ
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
HLMAF Max Drawdown
-21.51%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for HLMAF and SPY.
Company Overview
Halma plc
Other OTC
Halma plc, through its subsidiaries, provides technology solutions in the safety, health, and environmental markets. It operates through three segments: Safety, Environmental & Analysis, and Medical. The Safety segment provides fire detection, specialist fire suppression, elevator safety, security sensors, people and vehicle flow technologies, specialized interlocks that control critical processes safely, and explosion protection and corrosion monitoring systems. This segment serves elevator safety, fire suppression, people and vehicle flow, fire detection, pressure management, industrial access control, and safe storage and transfer markets. The Environmental & Analysis segment offers optical, optoelectronic, and spectral imaging systems; water, air and gases monitoring technologies; instruments that detect hazardous gases and analyses air quality; and systems for water analysis and treatment. It serves the optical analysis, water analysis and treatment, gas detection, and environmental monitoring markets. The Medical segment provides critical fluidic components used by medical diagnostics and original equipment manufacturers; laboratory devices and systems that provide information to understand patient health and enable providers to make decisions across the continuum of care; technologies and solutions to enable in-vitro diagnostic systems and life-science discoveries and development; and technologies that enable positive outcomes across clinical specialties. This segment serves the life sciences, health assessment, and therapeutic solutions market. The company was incorporated in 1894 and is headquartered in Amersham, the United Kingdom.
- Leadership
- Marc Arthur Ronchetti
- IPO Date
- Aug 15, 2012
- Employees
- 8.0k
- Street Address
- Misbourne Court
- Mailing
- Amersham, HP7 0DE
- Region
- Amersham, GB
- Reporting Currency
- USD
- Investor Line
- 44 1494 721111
- Last Updated
- Apr 29, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- 62.4
- EV/EBITDA
- 38.4
- Price/Sales
- 9.1
- Price/Book
- 8.4
Growth
- Revenue
- +10.5%
- EPS
- +9.9%
- Free Cash Flow
- +29.9%
Profitability
- Gross Margin
- 1.8%
- Operating Margin
- 20.2%
- Net Margin
- 14.6%
- ROE
- 13.7%
- ROIC
- 9.6%
Balance Sheet
- Debt/Equity
- 0.43
- Current Ratio
- 2.18
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.